News
12.07.22

Ocular Science Expands National Presence with Appointment of Dr. Chirag Shah to Medical Advisory Board

Dr. Shah, voted a New Jersey ‘Top Doc’, joins SoCal biotech board

EL SEGUNDO, Calif. (December 7, 2022) – With the appointment of Chirag Shah, MD to its medical advisory board, Southern California biotech Ocular Science® continues to extend its coast-to-coast presence. Dr. Shah, a specialist in corneal and refractive surgery and the founder of LASIK Experts in New Jersey and Pennsylvania, has performed more than 70,000 vision correction procedures and is one of the most experienced refractive and IOL surgeons on the East Coast. In addition to general cornea and cataracts, he specializes in procedures such as LASIK, PRK, SMILE, refractive lens exchange, ICL, premium IOLs and complex corneal treatments like ectasia and keratoconus with CXL and topography guided ablations. Dr. Shah is also a teaching attending physician at the Wills Eye Hospital.

He initially became familiar with Ocular Science in 2015 and its affiliate OSRX® in 2019, the year the 503A ophthalmic compounding pharmacy was founded to provide simplified, cost-effective compounded medications to physicians and patients for vision correction, myopia control and glaucoma management.

“Longtime friend (Ocular Science co-founder) Dr. Francis Mah introduced me to the organization, and I’ve watched its remarkable expansion to provide simple and affordable medications for patients,” says Dr. Shah. He has also been voted a Top New Jersey Doctor by fellow physicians for the past 12 years straight. “Their medical advisory board has also expanded; to nearly three dozen ophthalmology and optometry influencers from around the country, a brilliant collection of innovative minds that I’m excited to partner with and exchange ideas.”

The medical advisory board is designed to develop policies and strategies that promote enhanced clinical solutions, products and patient outcomes for Ocular Science and its affiliated PCAB-accredited pharmacy, OSRX, which currently compounds multiple medications into a single bottle to simplify dosing and promote easy patient adherence.

“Dr. Shah continually seeks to expand his surgical skills beyond the norms of ophthalmology and will be a brilliant addition to our board that seeks to expand beyond the norms of ophthalmic products”, says OSRX Chief Commercial Officer Eric Garner. “We are honored to welcome him into our Ocular Science family.”OSRX is a 503A compounding pharmacy that customizes OMNI by OSRX ophthalmic medications that are patient-specific and have been prescribed for surgical vision correction, myopia and glaucoma management. OSRX combines multiple medications into a single bottle to supply patients with simple-to-use, cost-efficient solutions by minimizing dosing complexity.

 

ABOUT OCULAR SCIENCE & OSRX

Ocular Science®, headquartered in El Segundo, Calif., was founded in 2015 by CEO Anthony Sampietro, Chief Medical Officer Damien Goldberg, MD, and Francis Mah, MD. The company is guided by a medical advisory board of world leaders in ophthalmology and focuses on the production, marketing and sales of compounded ophthalmic products. OSRX® – an affiliate of Ocular Science – is a PCAB-accredited 503A compounding pharmacy located in Missoula, Mont. that prepares customized medications in four areas of ophthalmology.

Professional Disclosure: Dr. Mah and Dr. Shah are on the Medical Advisory Board of Ocular Science (an affiliate of OSRX) and have a financial interest in the company. References available upon request.

OSRX operates in full compliance with Section 503A regarding compounded drugs as defined in the FD&C Act.

*Compounded drugs are not FDA-approved, which means they have not undergone FDA premarket review for safety, effectiveness, and quality. 503A compounding pharmacies are not required to comply with cGMP requirements but can be inspected by FDA. References available upon request.

Click here to view potential contraindications.